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Although it is well established that cGMP has important
(patho-)physiological functions, the downstream media-
tors of cGMP signalling are not well understood. The
cGMP-dependent protein kinase type I (cGKI) is an attrac-
tive candidate receptor for cGMP. A common approach to
distinguish between cGKI-dependent and cGKI-inde-
pendent cGMP effects is the use of pharmacological "cGKI
inhibitors". However, it is increasingly recognized that
some of these drugs, such as KT5823, may be less specific
than previously thought or may not at all inhibit cGKI
activity in intact cells. The Rp-cGMP analogs are reported
to inhibit cGKI by binding to the cGMP-binding sites. In
this study, we have analysed the effects of two popular Rp-
cGMP analogs, Rp-8-Br-PET-cGMPS and Rp-8-pCPT-
cGMPS, on basal and cGMP/cGKI-stimulated growth of
vascular smooth muscle cells. Surprisingly, neither com-
pound showed a clear inhibition of cell growth and cGKI
activity in intact cells as monitored by growth assays and
phosphorylation of vasodilator-stimulated phosphopro-
tein (VASP), respectively. In vitro kinase assays with puri-
fied cGKI demonstrated that both Rp-cGMP analogs are
partial agonists for cGKI rather than antagonists (see Fig-
ure 1). Thus, it appears difficult to interpret data obtained
from experiments with Rp-8-Br-PET-cGMPS and Rp-8-
pCPT-cGMPS. Both compounds should be used with cau-
tion as "cGKI inhibitors".
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Effects of the Rp-cGMP isomers on basal cGKI activity in vitroFigure 1
Effects of the Rp-cGMP isomers on basal cGKI activity in 
vitro.
